Bristol-Myers Squibb (BMS) just announced that it will shift its strategic focus in R&D by ending new work in
diabetes, hepatitis C and neuroscience and pouring more resources into
immune system-based cancer therapies.
Remember what I told you about my speculation that Novartis may merge with BMS? The key interest for Novartis is BMS immune oncology portfolio. Now with BMS to enhance its immune oncology and to slim itself, I think BMS will become more attractive to Novartis. I bet a deal is under active discussion and it is becoming more likely this marriage will become a reality!
No comments:
Post a Comment